Concerning the subgroup of myeloid malignancies, KIR-ligand mismatch resulted in worse OS at 5 years [13 versus 38%, P < 0.01, no use of antithymocyte globulin (ATG)], which was even more surprising. Here, KIR3DL1 is linked to myeloid neoplasm.